UK Markets closed

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
441.00-20.00 (-4.34%)
At close: 04:35PM GMT
Full screen
Previous close461.00
Bid0.00 x 0
Ask535.00 x 0
Day's range433.50 - 479.00
52-week range337.00 - 656.00
Avg. volume170,338
Market cap3.813B
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-18.40
Earnings date28 Jul 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.34
  • Globe Newswire

    HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

    HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (“CSF-1R”) inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability,

  • Globe Newswire

    HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US. Further details of the presenta

  • Globe Newswire

    HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (“ITP”) patients who have received at le